Inflammopharmacology

Psoriasis and body-wide inflammation linked to metabolic and liver health problems

Updated

Abstract

Psoriasis affects approximately 2-3% of the global population and is associated with up to 50% risk of systemic comorbidities.

  • Psoriasis is being reclassified as a systemic inflammatory disease rather than just a skin condition.
  • Pro-inflammatory mediators such as TNF-α, IL-17, IL-23, and IL-6 contribute to both skin symptoms and systemic complications.
  • Common pathways including TNF-α/NF-κB activation and the IL-23/Th17 axis are linked to psoriatic disease and metabolic disorders.
  • Patients with psoriasis show a high prevalence of obesity, type 2 diabetes, and dyslipidaemia regardless of other risk factors.
  • Recognizing psoriasis as a systemic condition calls for a shift toward comprehensive management strategies that address both skin and metabolic health.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declarations. Conflict of interest: The authors have no relevant financial or non-financial interests to disclose. Ethics approval: Not applicable. This article does not contain any studies involving human participants or animals performed by any of the authors.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free